Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $7.20.

PYXS has been the subject of several research analyst reports. Guggenheim upped their target price on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research report on Monday, November 3rd. They issued a “buy” rating and a $9.00 target price on the stock. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. Finally, Zacks Research lowered shares of Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th.

Pyxis Oncology Stock Up 2.7%

Shares of Pyxis Oncology stock opened at $1.52 on Friday. The firm has a market cap of $94.64 million, a PE ratio of -0.95 and a beta of 1.45. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.55. The business has a 50-day moving average price of $1.46 and a 200 day moving average price of $2.48.

Institutional Trading of Pyxis Oncology

Institutional investors have recently made changes to their positions in the company. Laurion Capital Management LP raised its stake in Pyxis Oncology by 32.3% in the 4th quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after purchasing an additional 1,170,505 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after buying an additional 14,566 shares in the last quarter. 683 Capital Management LLC raised its position in shares of Pyxis Oncology by 69.9% in the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after buying an additional 366,910 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Pyxis Oncology by 158.8% in the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock worth $904,000 after buying an additional 482,310 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Pyxis Oncology by 26.4% in the fourth quarter. Renaissance Technologies LLC now owns 728,380 shares of the company’s stock worth $838,000 after buying an additional 152,044 shares in the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.